Abe M, Takahashi M, Shibamoto Y
Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1083-6.
Clinical results of intraoperative radiotherapy (IOR) applied to carcinomas of the stomach, pancreas, and rectum were reported. In stomach cancer, the 5-year survival rates of patients treated by operation alone were 93.0% for stage I, 61.2% for stage II, 36.8% for stage III and 0% for stage IV. On the other hand, the 5-year survival rates of patients treated by IOR were 90.2% for stage I, 77.0% for stage II, 54.4% for stage III and 15.3% for stage IV. It has been demonstrated that IOR has definite effects on locally advanced gastric cancer. In pancreatic cancer, the median survival times for all patients treated by operation alone, IOR and IOR+ external beams were 3.5 months, 4.5 months and 8 months respectively. The median survival times of stage III patients treated by operation alone, IOR and IOR+ external beams were 5.5 months, 5.5 months and 12 months respectively. Our clinical results suggest that prolongation of life can be expected in patients who are treated by IOR followed by external beams and stage III is best indicated. In rectal cancer, it was found that stage IV as classified according to the rules for colorectal cancer studies in Japan is best indicated for IOR from the analysis of the survival figures. In stage IV patients, those who received operation alone could not survive more than 50 months while about 50% of those who were treated by IOR are alive 50 months after the treatment.
报告了术中放疗（IOR）应用于胃癌、胰腺癌和直肠癌的临床结果。在胃癌中，单纯手术治疗患者的5年生存率为：I期93.0%，II期61.2%，III期36.8%，IV期0%。另一方面，接受术中放疗患者的5年生存率为：I期90.2%，II期77.0%，III期54.4%，IV期15.3%。已证明术中放疗对局部进展期胃癌有确切疗效。在胰腺癌中，单纯手术治疗、术中放疗和术中放疗+外照射治疗的所有患者的中位生存时间分别为3.5个月、4.5个月和8个月。III期患者单纯手术治疗、术中放疗和术中放疗+外照射治疗的中位生存时间分别为5.5个月、5.5个月和12个月。我们的临床结果表明，接受术中放疗后再行外照射治疗的患者有望延长生命，III期患者最适合该治疗。在直肠癌中，根据日本结直肠癌研究规则分类的IV期患者，从生存数据分析来看最适合术中放疗。在IV期患者中，单纯手术治疗的患者存活时间不超过50个月，而接受术中放疗治疗的患者约50%在治疗后50个月仍存活。
